Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Glioblastoma × Valganciclovir × Clear all

Phase

Status

Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1 Thrombocythemia, Essential 1 Sezary Syndrome 1 Primary Myelofibrosis 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1 Pdgfra-Associated Chronic Eosinophilic Leukemia 1 Neoplasms 1 Myeloproliferative Disorders 1 Mycosis Fungoides 1 Multiple Myeloma 1 Multi-centric Castleman's Disease 1 Macular dystrophy, corneal type 1 1 Lymphoproliferative Disorders 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, Extranodal NK-T-Cell 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphadenopathy 1 Leukemia, Prolymphocytic 1 Leukemia, Neutrophilic, Chronic 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

Temozolomide 45 Radiotherapy 20 Radiation 13 Nivolumab 9 Magnetic Resonance Spectroscopy 9 pembrolizumab 8 Specimen Handling 7 Bevacizumab 7 poly ICLC 4 atezolizumab 4 Lomustine 4 olaparib 3 Surgical Procedures, Operative 3 Photons 3 Ipilimumab 3 Immunoglobulin G 3 Disulfides 3 Cyclophosphamide 3 veliparib 2 trametinib 2 sargramostim 2 rocakinogene sifuplasmid 2 pamiparib 2 niraparib 2 dabrafenib 2 azeliragon 2 Transurethral Resection of Bladder 2 Surveys and Questionnaires 2 Standard of Care 2 Receptors, Interleukin-8B 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04116411 2025-12-22

VIGAS2

Karolinska Institutet

Phase 2 Active not recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡